62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial

C. Zhou,S. Ren, J. Chen, X. Xu,Y. Cheng, G. Chen, Y. Pan,Y. Fang,Q-M. Wang, Y. Huang, W. Yao,R. Wang, X. Li,W. Zhang, Y. Zhang, S. Hu, R-H. Guo,D. Wang, Z. Wang, X. Lu

ESMO Open（2024）

Cited 0|Views11

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined